

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Apr 2019 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Adalimumab	Humira	Eye	Approved	
2	Asunaprevir	Sunvepra	Infections	Approved	
3	Daclatasvir	Daklinza	Infections	Approved	
4	Baricitinib	Olumiant	Musculoskeletal and joint disease	Approved	
5	Bictegravir/emtricitabine/tenofovir alafenamide fumarate	Biktarvy	Infections	pending	Pending further information
6	Dabrafenib / Trametinib	Tafinlar / Mekinist	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
7	Eltrombopag	Revolade	Nutrition and blood	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
8	Etelcalcetide	Parsabiv	Nutrition and blood	Approved	
9	Fentanyl	Fentora	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
10	Ibrutinib	Imbruvica	Malignant disease and immunosuppression	Approved	
11	L-ornithine-L-aspartate	Hepa-Merz	Nutrition and blood	Rejected	Lack of high quality level of evidence to demonstrate its efficacy
12	Midostaurin	Rydapt	Malignant disease and immunosuppression	pending	Pending further information
13	Omalizumab	Xolair	Respiratory system	Approved	
14	Oxycodone	OxyContin / OxyNorm	Central nervous system	pending	Pending further information
15	Palbociclib / Fulvestrant	Ibrance / Faslodex	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
16	Tafluprost eye drop preservative free	Taflotan-S	Eye	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.